HA
OLMA icon

HHLR Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

HHLR Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-620,397
Closed -$17.4M – 102
2021
Q2 		$17.4M Hold
620,397
– – 0.18% 56
2021
Q1 		$20.6M Hold
620,397
– – 0.2% 46
2020
Q4 		$29.8M Buy
+620,397
New +$29.1M 0.24% 49

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors's OLMA Position: Q3 2021 in Review

HHLR Advisors sold out of Olema Pharmaceuticals (OLMA) in Q3 2021, closing a stake of 620,397 shares — an estimated $17.4M sold.

HHLR Advisors first reported a position in OLMA in Q4 2020 and held it in 3 quarters. The position peaked at $29.8M in Q4 2020. 76 funds tracked by Wall St. Rank hold OLMA as of Q3 2021.

  • HHLR Advisors reported no remaining Olema Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • HHLR Advisors sold 620,397 Olema Pharmaceuticals shares in Q3 2021, an estimated $17.4M.
  • HHLR Advisors first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • HHLR Advisors's Olema Pharmaceuticals position peaked at $29.8M in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.